Valuation: InspireMD Inc

Market Cap 20.92M 18.74M 17.23M 15.62M 29.19M 1.99B 29.74M 206M 82.5M 1.04B 78.51M 76.84M 3.3B P/E 2026 *
-
P/E 2027 * -
Enterprise Value 20.92M 18.74M 17.23M 15.62M 29.19M 1.99B 29.74M 206M 82.5M 1.04B 78.51M 76.84M 3.3B EV / Sales 2026 *
2.13x
EV / Sales 2027 * 1.04x
Free-Float
80.03%
Yield 2026 *
-
Yield 2027 * -
Manager TitleAgeSince
Chief Executive Officer 62 31/12/2019
Director of Finance/CFO 58 24/06/2025
Chief Tech/Sci/R&D Officer - -
Director TitleAgeSince
Chairman 71 01/06/2017
Director/Board Member 68 06/02/2013
Director/Board Member 62 31/12/2019
Change 5-day change 1-year change 3-year change Capi.($)
+2.50%+3.31%-12.51%+12.91% 184B
+1.51%+3.00%+8.24%+35.43% 118B
+4.44%-1.36%-15.69%+8.53% 111B
+1.41%+6.80%-41.04%+6.45% 94.58B
+0.78%+0.99%-2.25%+73.41% 63.13B
-5.48%-5.08%-1.24%+63.86% 55.66B
+0.78%+1.02%+11.90%-22.48% 53.9B
+19.03%+13.21%-10.70%+53.91% 43.42B
+2.20%+4.18%+2.41%-8.38% 34.68B
Average +3.05%+0.06%-6.76%+24.85% 84.27B
Weighted average by Cap. +2.59%+0.24%-9.10%+22.61%

Financials

2026 *2027 *
Net sales 9.8M 8.78M 8.07M 7.31M 13.67M 930M 13.93M 96.27M 38.65M 489M 36.78M 35.99M 1.54B 20.13M 18.03M 16.58M 15.03M 28.09M 1.91B 28.62M 198M 79.39M 1.01B 75.55M 73.95M 3.17B
Net income - -
Net Debt - -
Logo InspireMD Inc
InspireMD, Inc. is a medical device company. The Company is focusing on the development and commercialization of its MicroNet stent platform technology for the treatment of vascular and coronary disease. Its MicroNet, a micron mesh sleeve, is wrapped over a stent to provide embolic protection in stenting procedures. Its CGuard carotid embolic prevention system (CGuard EPS) combines its MicroNet and a self-expandable nitinol stent in a single device for use in carotid artery applications. Its MGuard Prime Embolic Protection System (MGuard Prime EPS) is marketed for use in patients with acute coronary syndromes, notably acute myocardial infarction (heart attack) and saphenous vein graft coronary interventions (bypass surgery). It markets and sells MGuard Prime EPS, a bare-metal cobalt-chromium based stent, for the treatment of coronary disease in the European Union. It is also developing a neurovascular flow diverter (NGuard), which is an endovascular device.
Employees
-